Current markers include plasma levels of chromogranin A, tumor metastases and Ki67 staining to determine the tumor proliferation rate. Previous studies have shown that FDG-PET for neuroendocrine ...

The detection of metastases in Merkel cell carcinoma (MCC) requires additional testing, such as pancytokeratin (panCK) or CK20, with no guarantee of success. Recent findings have identified ...

Identical to MIB1. ‡ Gastrointestinal neuroendocrine tumor. § Pancreatic neuroendocrine tumor. NET: Neuroendocrine tumor. Data from [20,94]. T1 Tumor limited to the pancreas and size <2 cm T2 ...

Pathologist Michael Roehrl is part of a multidisciplinary team that evaluates and treats hundreds of people with neuroendocrine tumors every year. At Memorial Sloan Kettering Cancer Center, our ...

Neuroendocrine tumors, including small cell lung cancer ... "We examined the levels of certain biochemical markers in the mice serum samples to ensure the SSO treatment did not induce any liver ...

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

It mainly arises from neuroendocrine (NE ... finding that these markers were elevated in the cancer cells compared to adjacent healthy cells. They also observed that as the cancer progressed ...

Ki-67: marker of tumor cell proliferation ... Somatostatin analogues: drugs mimicking somatostatin, often used with other treatments for neuroendocrine tumors. Patients treated with 177Lu-edotreotide ...

Histotripsy, a non-invasive procedure for liver cancer treatment, is now available in Metairie, offering hope to patients in a state with high liver cancer rates.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...